CAGAS
ALXN

Capital Advisory Group Advisory Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-54
Closed -$10K – 584
2021
Q2 		$10K Hold
54
– – ﹤0.01% 401
2021
Q1 		$8K Hold
54
– – ﹤0.01% 417
2020
Q4 		$8K Hold
54
– – ﹤0.01% 397
2020
Q3 		$6K Hold
54
– – ﹤0.01% 374
2020
Q2 		$6K Hold
54
– – ﹤0.01% 366
2020
Q1 		$5K Buy
+54
New +$5.3K 0.01% 315
2019
Q4 		– Sell
-54
Closed -$5K – 456
2019
Q3 		$5K Hold
54
– – ﹤0.01% 349
2019
Q2 		$7K Buy
+54
New +$6.96K ﹤0.01% 323

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Capital Advisory Group Advisory Services's ALXN Position: Q3 2021 in Review

Capital Advisory Group Advisory Services sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 54 shares — an estimated $10K sold.

Capital Advisory Group Advisory Services first reported a position in ALXN in Q2 2019 and held it in 8 quarters. The position peaked at $10K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Capital Advisory Group Advisory Services reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Capital Advisory Group Advisory Services sold 54 Alexion Pharmaceuticals shares in Q3 2021, an estimated $10K.
  • Capital Advisory Group Advisory Services first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 8 quarters.
  • Capital Advisory Group Advisory Services's Alexion Pharmaceuticals position peaked at $10K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Capital Advisory Group Advisory Services's 13F filing for Q3 2021, filed 12 Nov 2021.